Yu Ai-Ping, Shi Bing-Xing, Dong Chun-Na, Jiang Zhong-Hua, Wu Zu-Ze
Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China.
Sheng Wu Gong Cheng Xue Bao. 2005 Jul;21(4):553-7.
To combine the fibrinolytic with anticoagulant activities for therapy of thrombotic deseases, a fusion protein made of tissue-type plasminogen activator (t-PA) and hirudin was constructed and expressed in chia pastoris. To improve thrombolytic properties of t-PA and reduce bleeding side effect of hirudin, FXa-recognition sequence was introduced between t-PA and hirudin molecules.The anticoagulant activity of hirudin can be target-released through cleavage of FXa at thrombus site. t-PA gene and hirudin gene with FXa-recognition sequence at its 5'-terminal were obtained by RT-PCR and PCR respectively. The fusion protein gene was cloned into plasmid pIC9K and electroporated into the genome of Pichia pastoris GS115. The expression of fusion protein was induced by methanol in shaking flask and secreted into the culture medium. Two forms of the fusion protein, single-chain and double-chain linked by a disulfide bond (due to the cleveage of t-PA at Arg275-Ile276), were obtained. The intact fusion protein retained the fibrinolytic activity but lacked any anticoagulant activity. After cleavage by FXa, the fusion protein liberated intact free hirudin to exert its anticoagulant activity. So, the fusion protein is a bifunctional molecule having good prospect to develop into a new targeted therapeutic agent with reduced bleeding side effect for thrombotic diseases.
为了将纤溶活性与抗凝活性结合起来用于治疗血栓性疾病,构建了一种由组织型纤溶酶原激活剂(t-PA)和水蛭素组成的融合蛋白,并在巴斯德毕赤酵母中进行表达。为了改善t-PA的溶栓特性并降低水蛭素的出血副作用,在t-PA和水蛭素分子之间引入了FXa识别序列。水蛭素的抗凝活性可通过血栓部位的FXa切割实现靶向释放。分别通过RT-PCR和PCR获得了5'-末端带有FXa识别序列的t-PA基因和水蛭素基因。将融合蛋白基因克隆到质粒pIC9K中,并通过电穿孔导入巴斯德毕赤酵母GS115的基因组。在摇瓶中用甲醇诱导融合蛋白表达,并分泌到培养基中。获得了两种形式的融合蛋白,一种是单链的,另一种是通过二硫键连接的双链形式(由于t-PA在Arg275-Ile276处的切割)。完整的融合蛋白保留了纤溶活性,但缺乏任何抗凝活性。经FXa切割后,融合蛋白释放出完整的游离水蛭素以发挥其抗凝活性。因此,该融合蛋白是一种双功能分子,具有开发成为一种新型靶向治疗剂的良好前景,可减少血栓性疾病的出血副作用。